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Primary resistance to tyrosine-kinase inhibitors (TKIs) is quite uncommon in chronic-phase Chronic
Myeloid Leukemia (CML) and related to still poorly understood mechanisms, as ABL mutations are rarely
detected in primary resistant patients. We report the challenging case of a CML patient who was resistant
to multiple TKIs because of different emerging ABL mutations and became pregnant while on Nilotinib
therapy despite repeated and clear discouragement to conceive. She decided to continue with her
pregnancy, showing an admirable and incredible perseverance in the pursuit of her personal aims.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Case report
Imatinib has radically changed prognosis in chronic-phase
Chronic Myeloid Leukemia (CML), with 90% overall survival rate at
8 yrs, and 40–70% of patients achieving a stable MMR [1]. Even
better results have been reported in terms of cytogenetic and
molecular responses and the rate of progression to accelerated/
blast phase using second-generation tyrosine-kinase inhibitors
(TKI) ﬁrst-line [2,3]. Physicians are no longer familiar with re-
sistant chronic-phase CML and are particularly frustrated when
facing primary resistance to TKIs, as it is quite uncommon and
related to still poorly understood mechanisms. Point mutations
within the BCR-ABL kinase domain account for 50–60% of cases of
secondary resistance to Imatinib and to a lesser extent to sec-
ondary resistance to second-generation TKIs [4]. However, ABL
mutations are less frequently detected in primary resistant pa-
tients and mutational analysis is not required by European Leu-
kemiaNet (ELN) Recommendations at diagnosis [5]. We report a
CML patient who showed resistance to multiple TKIs because of
different emerging ABL mutations, but who showed an admirable
and incredible perseverance in the pursuit of her personal aims.
Our patient (a 24-year-old woman) arrived in Italy from Eastern
Europe in March 2013 as an illegal immigrant. Three months later
she was admitted to our hospital. Her blood counts were as fol-
lows: leukocytes 410.7109/L, platelets 391109/L, Hb 11 g/dl,
with immature myeloid cells at differential count. SplenomegalyLtd. This is an open access article u
di).was palpable 4 cm below costal margin. Cytogenetic analysis on
the bone marrow aspirate revealed t(9;22)(q34;q11) in 20/20
metaphases without additional abnormalities, and a BCR-ABL re-
arrangement (e14a2) was detected by qualitative RT-PCR. Chronic-
phase CML was diagnosed as low risk according to Sokal score.
Two leukapheresis procedures were performed and cytarabine
(800 mg for two doses) was administered. Twenty days after ad-
mission Imatinib therapy was started at the dose of 400 mg OD. At
this time the blood counts were: leukocytes 37.4109/L, platelets
551109/L and Hb 12 g/dl. An ABL mutational analysis was per-
formed, although it was not required according to ELN Re-
commendations in chronic phase at diagnosis, and an F317L mu-
tation was detected by Sanger sequencing. This mutation is re-
sistant to dasatinib and sensitive to Imatinib albeit with higher
IC50 than wild type ABL. Accordingly, the Imatinib dose was in-
creased to 400 mg BID, but two months later hematologic re-
sponse was still inadequate. Considering the low age and the poor
response we applied for Nilotinb availability to treat our patient,
although she was living in Italy without regular assistance from
the National Health System. Nilotinib therapy was authorized by
local Regulatory Agency and was started in September 2013 at the
dose of 400 mg BID. A complete hematologic response was
achieved, but after three months of therapy the BCR-ABL transcript
level was still high (BCR-ABL/ABL 23% IS) without any cytogenetic
response. The mutational analysis was repeated and two further
mutations (F359V, E255V) both resistant to Nilotinib were dis-
covered. A switch to Ponatinib therapy was planned (according to
an individual use program) but at the end of January 2014 the
patient communicated to be pregnant, despite repeated and clearnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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continued (6 weeks gestation) and elective abortion was sug-
gested, because of risk of fetal abnormalities and refractory disease
requiring treatment. The patient initially agreed; however, just
prior to undergo the procedure she decided to continue with her
pregnancy, due to her own religious beliefs and desire of mo-
therhood. In the meanwhile, the WBC had increased to 101109/
L. Two leukapheresis procedures were performed resulting in a
decrease in the WBC to 40109/L. A spontaneous and unexpected
lowering of leukocyte count was observed that allowed the patient
to remain without treatment until May 2014. Then, IFN treatment
was refused by our patient and Hydroxyurea therapy was started
to control the disease (22 weeks gestation). A follow-up with ul-
trasound scan during the course of the pregnancy was un-
remarkable. Pregnancy was uneventful and at 36 weeks gestation
a healthy male infant was born after induction of delivery (weight:
2.4 Kg). The infant was well and no developmental abnormalities
were detected. Lactation was inhibited and Ponatinib was started
(45 mg OD). At this time, cytogenetic analysis showed 8/8 Ph-
positive metaphases; BCR-ABL transcript level was 63% IS and a
double BCR-ABL rearrangement was detected by FISH analysis.
Sanger sequencing showed F317L and F359V mutations. The pa-
tient is still on Ponatinib at the dose of 15 mg OD due to recurrent
grade III cytopenia and the transcript level was 4.28% IS at the last
check-up. The patient has two younger sisters (17-year old twins)
and one brother who are not allowed to move to Italy and could
therefore not be tested for the HLA compatibility. A full-matched
HLA identical unrelated donor has been identiﬁed, but the patient
decided to postpone the allogeneic transplant as she is not able to
manage the predictable issues related to the procedure in the
absence of an adequate familial support.
In this case we had to face two serious concurrent problems:
refractory CML and conception under second-line TKI. Primary
resistance to TKIs entails a very dismal prognosis. In our case ABL
mutations selected in sequence by the TKI in use were apparently
responsible for resistance to multiple TKI, but in addition genetic
instability typical of a more advanced phase might be hypothe-
sized in a patient who had most likely ignored her disease for
months. Ponatinib has been proven to be effective in heavily
pretreated CML patients independent of the presence of ABL
mutations [6]. However, genetic instability makes a long lasting
response quite unlikely. Allogeneic stem cell transplantation
seems to be the only meaningful option in this case, but we do not
know if our patient will ever undergo the procedure. Whereas
some reassuring data exists on unplanned conception under Im-
atinib treatment [7,8], very little information is available about the
safety of conception under Nilotinib [9,10], and female patients in
reproductive age are strongly advised to use effective methods of
contraception while receiving TKIs. Fortunately, the child is heal-
thy and developing normally. In our case the management of the
pregnancy posed challenges to both the patient and the physi-
cians, as our patient became pregnant on Nilotinib while strictly
requiring treatment to control her disease. Moreover, it required
delicate attention to important ethical and psychosocial issues,
including as well as cultural sensibilities. So far, the patient hasbeen conﬁdent in the good outcome of the whole clinical course,
often reassuring her increasingly worried physicians with a smile
and pictures of her son. This case reminds us that (i) CML is still a
life-threatening disease and we should not to lower our guard,
despite excellent results in the majority of patients and multiple
TKIs available; (ii) patients' personal social contexts and wishes
have to be respected, even if they contrast with rational adherence
to the treatment guidelines; and (iii) a patient's perseverance and
optimism are invaluable in the ﬁght against leukemia.Conﬂict of interest
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